Clinical Trials Sponsored by Kythera Biopharmaceuticals

Total 872 results

Kythera Biopharmaceuticals

Completed

Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Healthy | Submental Fat

United States, Canada, Australia, United Kingdom
Kythera Biopharmaceuticals

Completed

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

Efficacy | Safety | Moderate to Severe Convexity of Submental Fat

United States
Kythera Biopharmaceuticals

Completed

Condition of Submental Fullness and Treatment Outcomes Registry (CONTOUR)

Submental Fullness

United States, Canada
Kythera Biopharmaceuticals

Completed

Deoxycholic Acid Injection for the Treatment of Superficial Lipomas

Lipoma

United States
Kythera Biopharmaceuticals

Completed

Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Australia, Canada, United Kingdom
Kythera Biopharmaceuticals

Completed

Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals

Completed

Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

Healthy

United States
Kythera Biopharmaceuticals

Completed

Evaluation of the Effect of ATX-101 on QT/QTc Intervals (ATX-101-11-24)

Healthy

United States
Kythera Biopharmaceuticals

Completed

A Study to Assess Injection Comfort of Two Formulations of ATX-101

Healthy

United States
Kythera Biopharmaceuticals

Completed

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

Efficacy | Safety | Moderate to Severe Convexity of Submental Fat

United States
Kythera Biopharmaceuticals

Completed

Phase 2 Study for the Treatment of Superficial Lipomas

Lipoma

United States
Kythera Biopharmaceuticals

Completed

Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat (ATX-101)

Moderate or Severe Submental Fullness

United Kingdom, Canada, Australia
Kythera Biopharmaceuticals

Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

United States, Canada
Kythera Biopharmaceuticals

Completed

Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

Healthy

United States
Kythera Biopharmaceuticals

Completed

ATX-101 Abdominoplasty (ATX-101-08-10)

Characteristics of Subcutaneous Fat

United States
Kythera Biopharmaceuticals

Completed

Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Healthy | Submental Fat

United States, Canada
Kythera Biopharmaceuticals

Completed

To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101

Healthy

United States
Kythera Biopharmaceuticals

Completed

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals

Completed

Patient Experience Study of Deoxycholic Acid Injection

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals

Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area (REFINE-1)

Moderate or Severe Submental Fullness

United States, Canada
Kythera Biopharmaceuticals

Completed

Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue

Healthy

United States
Kythera Biopharmaceuticals
Bayer

Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Belgium, France, Germany, Italy, Spain, United Kingdom
Kythera Biopharmaceuticals
Bayer

Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Germany, France, Belgium, Spain, United Kingdom
OxThera

Completed

Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients (PHOENIX)

Primary Hyperoxaluria

United States
OxThera

Completed

Phase 2/3 Oxabact Study

Primary Hyperoxaluria

United States, Germany, Netherlands
OxThera

Terminated

An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria (ePHex-OLE)

Hyperoxaluria, Primary

United Kingdom, Spain, Belgium, United States, Germany, Tunisia
Angitia Biopharmaceuticals

Recruiting

A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion

Degenerative Disc Disease

China
Navidea Biopharmaceuticals

Recruiting

Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Rheumatoid Arthritis

United States
Eiger BioPharmaceuticals

Completed

A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)

Hepatitis D, Chronic

Israel, New Zealand, Pakistan
Angitia Biopharmaceuticals

Completed

A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease

Degenerative Disc Disease

China
Navidea Biopharmaceuticals

Completed

Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA

Arthritis, Rheumatoid

United States
Keryx Biopharmaceuticals

Completed

KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial) (COMPASS)

Chronic Kidney Diseases | Iron Deficiency Anemia

United States
Navidea Biopharmaceuticals

Withdrawn

Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid
Keryx Biopharmaceuticals

Completed

KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD

Anemia of Chronic Kidney Disease

United States
Keryx Biopharmaceuticals

Completed

Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis

Iron Deficiency Anemia | Iron Deficiency

United States
Navidea Biopharmaceuticals

Withdrawn

A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Parkinson's Syndrome

United States
Navidea Biopharmaceuticals

Unknown

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

Dementia | Alzheimer's Disease

United States
Eiger BioPharmaceuticals

Terminated

Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)

Hepatitis D

United States
Navidea Biopharmaceuticals

Terminated

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Nabi Biopharmaceuticals

Completed

Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever

Staphylococcal Infections
OMRIX Biopharmaceuticals

Completed

Safety and Hemostatic Efficacy of Fibrin Fleece in Partial Nephrectomy (Fleece)

Nephrectomy | Hemostatic Techniques

Israel
Nabi Biopharmaceuticals

Completed

StaphVAX in Cardiovascular Surgery Patients

Cardiovascular Diseases | Staphylococcal Infections | Cardiovascular Surgical Procedures

United States
XTL Biopharmaceuticals

Unknown

Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection

Hepatitis C

United States, Israel
Nabi Biopharmaceuticals

Completed

Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis

Kidney Failure, Chronic | Staphylococcal Infections
Keryx Biopharmaceuticals

Recruiting

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

Hyperphosphatemia Related to Chronic Kidney Disease

United States
Navidea Biopharmaceuticals

Recruiting

Comparison of Tc 99m Tilmanocept Quantitative Imaging With Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue of Subjects With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

United States, United Kingdom
Eiger BioPharmaceuticals

Completed

Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a (D-LIVR)

Hepatitis Delta Virus

United States, Belgium, Spain, Greece, Canada, Italy, Romania, Germany, Israel, Bulgaria, Taiwan, Turkey, Pakistan, Sweden, Ukraine, New Zealand, Russian Federation, United Kingdom, Moldova, Republic of, France, Mongolia, Switzerland
Eiger BioPharmaceuticals

Completed

A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (LIBERTY)

Pulmonary Arterial Hypertension

United States, Canada
Eiger BioPharmaceuticals

Completed

Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)

Lymphedema

United States, Australia
Eiger BioPharmaceuticals

Completed

Lonafarnib With and Without Ritonavir in HDV (LOWR-1) (LOWR-1)

Chronic Hepatitis D Infection

Turkey

3

Subscribe